<SEC-DOCUMENT>0001193125-25-311834.txt : 20251209
<SEC-HEADER>0001193125-25-311834.hdr.sgml : 20251209
<ACCEPTANCE-DATETIME>20251209060051
ACCESSION NUMBER:		0001193125-25-311834
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20251208
FILED AS OF DATE:		20251209
DATE AS OF CHANGE:		20251209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		251557523

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d70253d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as December 08, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#8217;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T
Rule&nbsp;101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by
Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">If &#8220;Yes&#8221; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not
applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><A HREF="d70253dex991.htm">Immutep and Dr. Reddy&#8217;s enters into Strategic Collaboration for Commercialisation of an Innovative
 Oncology Drug, Eftilagimod Alfa </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: December 08, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d70253dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g70253g01dsp4a.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">


<IMG SRC="g70253g01dsp4b.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="justify"><B>Immutep and Dr.&nbsp;Reddy&#8217;s enters into Strategic Collaboration for Commercialisation of an Innovative
Oncology Drug, Eftilagimod Alfa </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Dr.</I><I></I><I>&nbsp;Reddy&#8217;s receives exclusive rights to develop and commercialise Eftilagimod Alfa in all
countries outside North America, Europe, Japan, and Greater China </I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Under the terms, Immutep to receive upfront payment of USD 20</I><I></I><I>&nbsp;million (~AUD 30.2 million) and is
also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5</I><I></I><I>&nbsp;million (~AUD 528.4 million), plus double-digit royalties on commercial sales </I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Sydney, Australia/Hyderabad, India - December 08, 2025</B><B><I> </I></B><B>&#8211;</B> <U>Immutep</U><U> Limited</U> (ASX: IMM; NASDAQ: IMMP)
(&#8220;Immutep&#8221; or &#8220;the Company&#8221;), a late-stage immunotherapy company targeting cancer and autoimmune diseases and Dr.&nbsp;Reddy&#8217;s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, and along
with its subsidiaries, hereafter referred to as &#8220;Dr.&nbsp;Reddy&#8217;s&#8221;), today announced that their respective wholly-owned subsidiaries, Immutep SAS and Dr.&nbsp;Reddy&#8217;s Laboratories SA, have entered into a strategic
collaboration and exclusive licensing agreement for the development and commercialisation of Eftilagimod Alfa (efti) in all countries outside North America, Europe, Japan, and Greater China. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Efti is Immutep&#8217;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> novel immunotherapy that directly
activates the immune system to fight cancer, which is under evaluation in <FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91),</FONT> a registrational Phase III trial for the first-line therapy of
advanced or metastatic <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. Efti is also being investigated in other indications including head&nbsp;&amp; neck cancer, breast cancer, and soft tissue sarcoma. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The terms of the licensing agreement provide Immutep with significant milestones and preserves its ability to capture material future upside in the
licensed markets as efti advances commercially. Further, Immutep holds the global manufacturing rights to the product across all markets and will supply the product to Dr.&nbsp;Reddy&#8217;s in the licensed markets, while Immutep retains all rights
to the product in the key pharmaceutical markets, including North America, Europe, and Japan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Additionally, as per the agreement, Immutep will
receive from Dr.&nbsp;Reddy&#8217;s an upfront payment of USD 20&nbsp;million (~AUD 30.2 million). It is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5&nbsp;million
(~AUD&nbsp;528.4&nbsp;million), plus double-digit royalties on commercial sales in these markets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#8220;This collaboration marks our continuous
efforts to deliver <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> and innovative therapies for cancer treatment. Efti is a novel immunotherapy with the potential to set a new standard of care in
combination with pembrolizumab (Keytruda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>) and chemotherapy as first-line therapy for <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. Its broad potential extends to other
major cancers across multiple stages of disease. Through this agreement, we look forward to leveraging our expertise and strong market access to advance the development and commercialization of this promising cancer therapy in the licensed
markets,&#8221; stated M.V. Ramana, CEO &#8211; Branded Markets (India &amp; Emerging Markets), Dr. Reddy&#8217;s. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">&#8220;This agreement with
Dr.&nbsp;Reddy&#8217;s marks a significant milestone for Immutep and further validates the potential of efti. Dr.&nbsp;Reddy&#8217;s proven capabilities and reach in the licensed markets make them an ideal partner to maximise the impact of our
innovation and serve a large number of patients across the globe. Additionally, this partnership allows us to capture significant value for efti in the licensed markets, while retaining full rights in key markets such as North America, Europe, and
Japan, and ensures we remain very well-positioned for future value creation,&#8221; said Marc Voigt, CEO of Immutep. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g70253g01dsp4a.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">


<IMG SRC="g70253g01dsp4b.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Eftilagimod Alfa (Efti): </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Efti is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble
<FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist delivered subcutaneously that uniquely activates antigen-presenting cells or APCs (e.g., dendritic cells, monocytes) via major histocompatibility complex (MHC) class
II ligands. As an MHC Class&nbsp;II agonist, its activation of APCs engages the adaptive and innate immune system to initiate a broad anti-cancer immune response. This includes priming and activating cytotoxic T cells as well as generating important
<FONT STYLE="white-space:nowrap">co-stimulatory</FONT> signals&nbsp;&amp; cytokines that further boost the immune system&#8217;s ability to combat cancer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in a
pivotal Phase III trial called <FONT STYLE="white-space:nowrap">TACTI-004</FONT> <FONT STYLE="white-space:nowrap">(KEYNOTE-F91),</FONT> as well as head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma, and breast cancer. Its favourable
safety profile enables various combinations like with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy, radiotherapy, and/or chemotherapy. This has been demonstrated across early-stage trials
in NSCLC and HNSCC, which have laid the foundation for the larger randomized clinical trial in NSCLC. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug Administration (FDA).
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Dr.&nbsp;Reddy&#8217;s: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Dr.&nbsp;Reddy&#8217;s
Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven
by our purpose of &#8216;Good Health Can&#8217;t Wait&#8217;, Dr.&nbsp;Reddy&#8217;s offers a portfolio of products and services including APIs, generics, branded generics, biosimilars, innovative drugs, and OTC. Our major therapeutic areas of focus
are oncology, gastroenterology, cardiology, diabetology, pain management and dermatology. Our major markets include &#8211; USA, India, Russia&nbsp;&amp; CIS countries, China, Brazil, and Europe. As a company with a history of deep science that has
led to several industry firsts, Dr.&nbsp;Reddy&#8217;s continues to plan and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to
set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to:&nbsp;<U>www.drreddys.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>About Immutep: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Immutep is a late-stage biotechnology company
developing novel immunotherapies for cancer and autoimmune disease<I>.</I> The Company is a pioneer in the understanding and advancement of therapeutics related to <I>Lymphocyte Activation <FONT STYLE="white-space:nowrap">Gene-3</FONT> </I><FONT
STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#8217;s</FONT> ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise
to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com.</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><I>KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of
Merck&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Immutep Contacts: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Eleanor Pearson,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">+61 2 9066 4071; <U>eleanor.pearson@sodali.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Chris Basta, VP, Investor Relations and Corporate
Communications </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g70253g01dsp4a.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right">


<IMG SRC="g70253g01dsp4b.jpg" ALT="LOGO">
</TD></TR></TABLE> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Dr.&nbsp;Reddy&#8217;s Contacts:</B></P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Media Relations:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Priya K</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><U>priyak@drreddys.com</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Investors Relations:</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Aishwarya Sitharam</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><U>aishwaryasitharam@drreddys.com</U></P></TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g70253g01dsp4a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g70253g01dsp4a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  H *H# 1$  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_B@ H *
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M2:;C-RC%\UI1.[#-8G*L;]9HJ,L/?V3>KK+E;O9KW7>+Z6LU;J?N_P#M)?\
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MK6EEKVL?;W_!:[]E_P 4^.?V.O@!^US\(K34(/C+^R-8^"_%[:[H<:KK%O\
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7BY-:Q;7VVGKT,V[MZWU].W^2'5H(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g70253g01dsp4b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g70253g01dsp4b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L (4# 1$  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_B@ H *
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M?V1BU=7=317U>M+H'$=.H_&;A2HJ<W3CE>'3FHR<$^;.]')+E3U6[ZKN8/\
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M+"UJ4JV'J+$0ABZ&#FX*45&K7K8>DK.<8J44L13J*<.:$X.\).]SF]*_:X^
MNMJG]F^*?$4\MQI>G:S86C_"_P"*UKJ.KZ?JVI_#C2+"70M,N_!$&H:])/>_
M%[X8YM=&MKZ[AM/&^@:C/!%IUY]J2I8'$QO>$$E)Q;]M0:C*,:TFI251J.F'
MK:R:3=.<4^96,89YEM1J,*U5RE35:$/J>-4ZE-SPE/FI0EAU.K:6.P=U3C*2
MCB:4VE"7,M#2/VA_@)?:9;>+--\1PV]GK$?VJ"_N/!GBS1]0NX)KKX>VD-U+
M::AX;LM66"_;XJ_#RXL;BYMDCU'3O%%AJEF]QIL5Y=VJEA,3&3IR@VXZ64X2
M2LJK:3C-QT]C53L]'!Q>K2=T\TRZ<(UX5;1J*ZE*A7IRDF\,E)QG2C.TOKF&
M<6XI2A6C-7BI-7?#G[2_P2\6>(_"?A#1/&PF\4^-[O7['PWX>OO#OBS1=8NK
MOPSIVIZOJT-[8:WH6GW.B,NE:-JNI:>==CTU=;L;&XN]$;48$WE2P>(A"I4E
M3_=TE%SFITY12FXQBTXR:E[THQER\W*Y)2LRJ6;9?6JT:%/$7K8B56-*E*E6
MIU)2HQJ3FI1J4X.G[E*I.'M%%5(PE*GSI7.1\#_M(^!=3U#78O$.FZ3X%O5U
M'3K&"TAU%=:\33:WJ=[XBMK7P;XR\-:;HUKXA\*?$P6V@#48_"-_9ZC#KEEJ
M=O)X*U[Q8=/UX:1I4P=6*CR.556;;Y>6'+%0;J4YN3A.C>=O:)Q<;/VD*=XW
MY\/F^&J2J*K&&'ES0BHN?/6]K.55+#5Z,8*K0QBC2Y_82C)55/\ V>I7]G5Y
M*^K?MD_L_P!AIFE:YJ?B#6(_ FO>%?$OB:'QI>^ _','AR>QT#Q!\.?##V5M
M'>>&HM0UJXU;4?B=HD=BNC:?J5NR6FJBZE@:T92XY?BFY148NI&I"'LU5I.5
MYPK5+MJ;C%1C0E?FDGK&U[A4S[+(0A4G5FL-5H5JRKO#XA4G&E6PE!Q2=)3J
M2G/&4U%4X36D^9KE.Q\+?M ?!#5?%5M\/O">M3MK-YK-]HEI!I_@/QK9>'+C
M5[%/%37<$'BD^%[;PA( W@CQ1!%=IK+6MW=Z3)9VL\]U/:0SY3PN(C3=:<5R
M**DVZM-R47[-*\.=U/\ E[3;7+=*5VDDVMJ6:9=.O'"4:DG5E4E3BHX;$1I.
M:6(;2K>Q5#_F$Q"YO:<KE3<4W*45+\'OV8@#_P '$7[9((!!^$6L@@\@@^'?
MV?<@CN#7TF+_ .26P'_7^/\ Z7BC\ZRC_DZ&??\ 8#4_]-94?TL0PPV\8B@B
MCAB7)6.&-8XU+$LQ"(%4;F)8X')))Y)KY(_5TDE9))=EHB2@84 >=:[\*/ W
MB7Q'=^*M9TW4[G5]0TC0M"U$1>*?%ECH^I:9X8U;5-=\/Q:CX;T_7+7PYJ$^
MD:MK.IWMC?WFE3W\,ETRBZ\J.&./6->K""A%I14I27N0<HN<5"7+-Q<XJ48I
M.*DHNU[7U.6I@L/5K.O4C-U)4Z=.25>O&G*%*<ZE)3HQJ*C.4)SG*,Y4W-7M
MS622X/7/V:?A#KGB;1_$%YX?O8Y[&[U>_N]/L]?UNSTG7[G4O%6H>.94\1V<
M%\K:OIR^*M;UO5GT*XF_L#4&U:YL]8TO4M.@T^SLM8XS$1@Z:FK-))N,7**C
M35+W';W7[.,8\R7.N5.,HMR;YIY1@)UH5G2:E%SE*,:E2,*DI8AXK]ZE+WXJ
MO4J5/9M^RDZDE4A.*C&,M[^S!\#-1TV[TF^\#+=6-Y=:G<E9O$GBY[FQ35M$
M;P[/INBWYU_[?H&@6FDE8-#\-:'<Z=X>\-W$%KJ/A[3-+U*SM;N%+&8E24E4
MLTDO@IV?++GYI1Y>64W*_-.2<YIN,Y2BVF2R?+I0E3EADXR<]/:U[Q4Z7L73
MIR]KS4J4:=E3HTW"E1:C*E"$XQDNDB^!_P +H)]2GC\,%1JE_K.IW%H=<\1O
MI=O>^(M/\5:;KTNDZ.^KMI.A)K%OXW\6RZE!HEEI]O>:CKU_J\\3ZM(MZDO$
MUG;W_A48I\L.9J#IN"E+EYI<OLJ:CS-M*"BO=T-5EV"3FU1^.=2;3J57!2JQ
MKPJN$'4<*?M%B:[FJ<8J4JLYM<[YCS/XF?LD?![X@^'8]!DM/$/A&)KZ<W&I
M^#->GTW6KFRUN/XJ:?K&DOJ.I1:Q+;Z9JB?'#XDR:A%8+9SWBZ_)I]Q<2:-"
MFF5M0QV(HSYTXS=M(U(WBG'V,HRM%QO*+PU%IMM)P3MS:G)C,CP&,I>RE"I1
M3;O.A4<:CC46-A4AS353EA4CF.,4U%1<E6<7+D2BO5/$7P8^&GBW6-8UWQ%X
M:74]3U_1[O0=6FEU;78H+K3+_P .ZQX3OH5L;;5(;"VFO/#NO:GI-S?6EK!?
MSVTEMYMRTNG:;):81Q%:$8QC.T8R4HKEC=-3C-:M7:4XQDDVTFMM7?NJX'"U
MJDZE2ES3J0=.;<ZB3C*E4HR7*IJ*<J56<'**4FG&[O"#C;TGX3^ =#T&7PQI
MVB31Z!)XJT7QHFEW.N>(-0MK+7_#>KZ%KOA^32AJ.JW3Z/I6B:GX9T.?2O#>
ME/9^&["+3X[.VTF.REN+>92KU92YY2]_DE3YE&*;C-3C/FM%<TI*<E*<KS=[
MN5TK.G@L-2INC"FU2=:G74'4JRC&I1G3G2]FI3?LZ=.5*FZ=&GRT8*/+&FHM
MI\]I_P"SW\'=*OM"U+3_  3:6U[X9L;#3=#G74]=<V%CID_PCN;&!$DU1XYE
MMY_@1\)I ]PDTCGP?;"1W74M;&IT\57DI1=1M3;E)6CJW[>[>G_437V_Y^/M
M&V4,LP$)TJD,/%3HP5.E+FJ-P@I8&2BKS=U?+<$W>[?U>-_BGS4I/V;/@M)!
MHEH?!ACM/#T%M;:7:6_B3Q;:VBVUEI_P]TNSM[ZUMM>BM]7@M;/X4_#T6\.K
MQWT<-SX7LKZ-5OI;VYNJ^MXB\G[363;;<8-W;JR=FXWC=UJM^6VDVMDDE_96
M Y:<?86C2BHPBJM9+EC'#0BI)5$IJ,<'A;<_-9T8R7O.3>[H7P1^&/ACQ%9^
M*_#_ (;DTC7;*>\N5NK'7_$L,%Y->Z?/I;MK&FKK']EZZMK97=ZFDQZU9:A'
MHDU_J%WHZ6-W?WD\TRQ%:<'3E-2BTE9PA=)-/W7R\T;M+FY6N;EBI725KIY?
M@Z5:->G1Y*L7)\T:E5*3E&4?WD5/DJJ*G/D52,E3<YRIJ,I2;YQ?V=_AE9ZQ
MX<U*PLM;M6T3Q#X:\00VESXEUK7[.1_ MOXJ;P1HUNOBF\UV?P]X:\)7WC#6
MM4T/P_X/N/#>F6MU,MJ\$ND&?3)Z^MUG&<6X/GC.+:A&#7M'#VDOW:@I3J*G
M%2E44Y-*Z:EJ8_V7A(U*,HQJ+V=2E4495:E6-\,JWU:"]M*K*E2H2KU)TZ="
M5**;46G3O!P-^R]\$FMY(#X6U?S);K4KZ34A\0/B.-=:_P!6E^'DM]?GQ$/%
MHUX7[GX4^ (X+X:B+JRMO#Z6=E-;VNHZO#J#6-Q*>DXV22Y?94N6R59)<G)R
MV_?UKJUFYMM-J+0\GR]IIT9W;DW/ZSBO:N4GA&Y^U]O[7GO@<)RSY^>*HI1:
M4IJ77Z3\%_ACH>L0>(-*\*6UGJ]MK5YXA@O4O]7D:/6+^[\67UW>K%-J$D&9
M;KQQXJE\DQ&V0ZO*D<*1V]DEMG+$5I1<)3;BXJ+5HI.*5-):)=*5/7?W;MW;
MOO3R_!TJBJPH1C452552YIMJI*6(FY:R:UEB\0[6LO:-))**CP?AK]DG]GGP
M?^T!XO\ VI?#GPXM=,^/7CS29M#\6_$!/$'BVXN=7TJ>WT&UEM'T*\U^X\+6
M@>W\,:%&9;#0[6<"P5EE#SW33ZSQV*J86G@IU6\-2ES0I<E-*,DY._,H*;UG
M+1R:UVT5N:CDF5T,SKYQ2PJAF6)@Z=?$^UKMU(-4HN/LY571C=4*2O&G%^YO
-K*_T;7(>J% !0!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
